In conclusion, the ephrinB1/ERBB2 (in breast cancer) and ephrinB1/ERBB1 (in head and neck cancer) complexes induce MAPK pathway activation and are positively regulated by SRC and negatively regulated by PTPN13. Here, ERBB2 is linked to breast carcinoma.